Halozyme Therapeutics HALO Accrued Compensation
Accrued Compensation at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's accrued compensation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's accrued compensation?
- Halozyme Therapeutics (HALO) reported accrued compensation of $18.14M in Q1 2026.
- How has Halozyme Therapeutics's accrued compensation changed year-over-year?
- Halozyme Therapeutics's accrued compensation increased by 75.4% year-over-year, from $10.34M to $18.14M.
- What is the long-term trend for Halozyme Therapeutics's accrued compensation?
- Over 3 years (2022 to 2025), Halozyme Therapeutics's accrued compensation has grown at a 12.8% compound annual growth rate (CAGR), from $19.94M to $28.62M.
- What does accrued compensation mean?
- Employee wages, salaries, bonuses, commissions, and benefits earned but not yet paid as of the reporting date.